Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Quaini

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Circulation Research|September 6, 2005
Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survivalKonrad Urbanek, Marcello Rota, Stefano Cascapera, et al.
Cardiovascular Research|February 19, 2010
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic miceClaudia Colussi, Roberta Berni, Jessica Rosati, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 11, 2024
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint InhibitorsGiulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, et al.
Pharmacological Research|October 2, 2017
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitorsMonia Savi, Caterina Frati, Stefano Cavalli, et al.
Molecular Cancer Therapeutics|May 28, 2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMara A Bonelli, Andrea Cavazzoni, Francesca Saccani, et al.
Journal for Immunotherapy of Cancer|January 6, 2026
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapyFederica Pecci, Giulia Mazzaschi, Alessandra Dodi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating MutationSilvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
Current Drug Targets|January 27, 2015
Cardioprotection by Targeting the Pool of Resident and Extracardiac ProgenitorsKonrad Urbanek, Caterina Frati, Gallia Graiani, et al.
International Journal of Molecular Sciences|September 28, 2024
CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative PhaseBruno Lorusso, Antonella Nogara, Rodanthi Fioretzaki, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Circulation Research|September 6, 2005
Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survivalKonrad Urbanek, Marcello Rota, Stefano Cascapera, et al.
Cardiovascular Research|February 19, 2010
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic miceClaudia Colussi, Roberta Berni, Jessica Rosati, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 11, 2024
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint InhibitorsGiulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, et al.
Pharmacological Research|October 2, 2017
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitorsMonia Savi, Caterina Frati, Stefano Cavalli, et al.
Molecular Cancer Therapeutics|May 28, 2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMara A Bonelli, Andrea Cavazzoni, Francesca Saccani, et al.
Journal for Immunotherapy of Cancer|January 6, 2026
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapyFederica Pecci, Giulia Mazzaschi, Alessandra Dodi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating MutationSilvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
Current Drug Targets|January 27, 2015
Cardioprotection by Targeting the Pool of Resident and Extracardiac ProgenitorsKonrad Urbanek, Caterina Frati, Gallia Graiani, et al.
International Journal of Molecular Sciences|September 28, 2024
CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative PhaseBruno Lorusso, Antonella Nogara, Rodanthi Fioretzaki, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Pageof 11